Wedbush Reiterates Outperform on Sarepta Therapeutics, Maintains $224 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $224.

January 30, 2024 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Andreas Argyrides reaffirmed an Outperform rating on Sarepta Therapeutics with a $224 price target.
The reiteration of an Outperform rating by a reputable analyst like Andreas Argyrides from Wedbush is a positive signal for investors, suggesting a bullish outlook on the stock. The maintained price target of $224 indicates a belief in the company's potential for growth and is likely to be viewed favorably by the market, potentially driving short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100